Yezan Munther Haddadin serves as Executive at Outlook Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Yezan Munther Haddadin has executed 6 insider transactions totaling $104.5K, demonstrating a bullish approach to their equity position. Their most recent transaction on Mar 28, 2024 involved purchasing 1,881.71 shares valued at $22.2K.
Yezan Munther Haddadin currently holds 5,048.71 shares of Outlook Therapeutics, Inc. (OTLK), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Yezan Munther Haddadin has been a net buyer of OTLK stock. They have purchased $104.5K and sold $0 worth of shares.
Yezan Munther Haddadin's most recent insider trade was on Mar 28, 2024, when they purchased 1,881.71 shares at $11.82 per share.
Get notified when new Form 4 filings are submitted
| $1.27 |
| Discretionary |
| Oct 6, 2022 | OTLK | $38.4K | Purchase | 29,743 | $1.29 | Discretionary |
| Dec 2, 2021 | OTLK | $13.9K | Purchase | 10,000 | $1.39 | Discretionary |
| Apr 19, 2021 | OTLK | $18.2K | Purchase | 10,000 | $1.82 | Discretionary |
| Sep 22, 2020 | OTLK | $7.2K | Purchase | 10,000 | $0.72 | Discretionary |